Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib
Abstract Background There has been a recent surge in interest in predicting biological effects associated with genomic alterations in order to implement personalized cancer treatment strategies. However, no reports have yet evaluated the utility of profiling blood-based circulating tumor DNA (ctDNA)...
Main Authors: | Yasutoshi Fujii, Atsushi Ono, C. Nelson Hayes, Hiroshi Aikata, Masami Yamauchi, Shinsuke Uchikawa, Kenichiro Kodama, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Wataru Okamoto, Tomokazu Kawaoka, Masataka Tsuge, Michio Imamura, Kazuaki Chayama |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13046-021-02016-3 |
Similar Items
-
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
by: Yusuke Kawamura, et al.
Published: (2020-10-01) -
Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib
by: Atsushi Ono, et al.
Published: (2020-05-01) -
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
by: Keisuke Koroki, et al.
Published: (2021-04-01) -
Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
by: Jonathan T. Hunt, et al.
Published: (2021-08-01) -
Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
by: Ai Kuwahara, et al.
Published: (2020-08-01)